05.02.24
Charles River Laboratories International, Inc. has launched its reference materials for its adeno associated virus (AAV) and lentiviral vector (LVV) portfolio, which is designed to streamline Cell and Gene Therapy (CGT) research and development as it scales to Good Manufacturing Practice- (GMP) quality.
“The launch of Charles River’s AAV and LVV reference materials portfolio is the latest in a series of enhancements in our CDMO products and services offerings,” says Ramin Baghirzade, PhD, Senior Director, Global Head Commercial, Gene Therapy CDMO Services, Charles River.
Charles River is introducing six AAV reference material serotypes, offering superior empty and full capsid ratios and high vector genome concentration (GC/mL), plus five LVV reference material products, available with different combinations of promoters and reporter genes.
The additional reference materials add to the Company’s portfolio of plasmid and viral vector contract development and manufacturing organization (CDMO) offerings, reinforcing its concept-to-cure commitment to CGT researchers and developers by enabling partners to navigate the path from early discovery to commercial.
“This expansion of the CGT product portfolio empowers our partners to navigate the path from research to commercialization under one organization, providing a streamlined process. Combined with Charles River’s established CDMO capabilities, this enables us to continue to work towards our ultimate goal of delivering safe, effective therapies to patients faster,” adds Kerstin Dolph, Corporate Senior Vice President, Global Manufacturing, Charles River.
“The launch of Charles River’s AAV and LVV reference materials portfolio is the latest in a series of enhancements in our CDMO products and services offerings,” says Ramin Baghirzade, PhD, Senior Director, Global Head Commercial, Gene Therapy CDMO Services, Charles River.
Charles River is introducing six AAV reference material serotypes, offering superior empty and full capsid ratios and high vector genome concentration (GC/mL), plus five LVV reference material products, available with different combinations of promoters and reporter genes.
The additional reference materials add to the Company’s portfolio of plasmid and viral vector contract development and manufacturing organization (CDMO) offerings, reinforcing its concept-to-cure commitment to CGT researchers and developers by enabling partners to navigate the path from early discovery to commercial.
“This expansion of the CGT product portfolio empowers our partners to navigate the path from research to commercialization under one organization, providing a streamlined process. Combined with Charles River’s established CDMO capabilities, this enables us to continue to work towards our ultimate goal of delivering safe, effective therapies to patients faster,” adds Kerstin Dolph, Corporate Senior Vice President, Global Manufacturing, Charles River.
